NU Skin Enterprises, Inc.
Wholesale drugs, proprietaries & druggists’ sundries10 peers
- Last sale
- Nov 12, 2026 · +3.47%
- Market cap
- $195.69M
- 48.68M shares
- Filings
- 1,019
Q3 2026−14.3% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derived−34.4% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+27.7% FY25 yoy
- $195.69M
- —
- 0.1×
- 0.4×
- -13.42%
- 5.94%
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $1,485,159,000 | reported | |
| FY 2024 | 2024-12-31 | $1,732,084,000 | reported | |
| FY 2023 | 2023-12-31 | $1,969,131,000 | reported | |
| FY 2022 | 2022-12-31 | $2,225,659,000 | reported | |
| FY 2021 | 2021-12-31 | $2,695,669,000 | reported | |
| FY 2020 | 2020-12-31 | $2,581,934,000 | reported | |
| FY 2019 | 2019-12-31 | $2,420,416,000 | reported | |
| FY 2018 | 2018-12-31 | $2,679,008,000 | reported | |
| FY 2017 | 2017-12-31 | $2,279,099,000 | reported | |
| FY 2016 | 2016-12-31 | $2,207,797,000 | reported | |
| FY 2015 | 2015-12-31 | $2,247,047,000 | reported | |
| FY 2014 | 2014-12-31 | $2,569,495,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $11.83M | $20.04M | $31.87M | — | 48.13M sh | −3.2% | 69.3% |
| FY2024 | $11.93M | $0.00 | $11.93M | — | 49.72M sh | +0.6% | 17.0% |
| FY2023 | $77.62M | $13.01M | $90.63M | — | 49.42M sh | −0.1% | 150.7% |
| FY2022 | $77.02M | $70.05M | $147.06M | — | 49.46M sh | −0.7% | 300.1% |
| FY2021 | $76.27M | $80.42M | $156.69M | — | 49.82M sh | −2.0% | 214.7% |
Segments
LineFY2025ShareChange
Americas$282.98M19%−12.3%
Southeast Asia/Pacific$209.80M14%−14.3%
Manufacturing$205.79M14%+2.2%
Mainland China$195.55M13%−16.9%
Japan$174.36M12%−4.0%
Europe & Africa$150.15M10%−8.5%
South Korea$130.22M8.8%−20.5%
Other$135.17M9.1%−37.4%
Total$1.49B
Wholesale drugs, proprietaries & druggists’ sundries
NU Skin Enterprises, Inc. is the 5th largest of the 11 covered companies the SEC files under this code, by revenue. SIC 5122
CompanyRevenueGrowthNet marginMarket cap
MCKMcKesson Corp$403.4B12.4%1.2%$124.3BCORCencora, Inc.$321.3B9.3%0.5%$66.7BCAHCardinal Health Inc$254.2B14.2%0.7%$64.3BHLFHerbalife Ltd.$5.0B0.9%4.5%$1.6B
NUSNU Skin Enterprises, Inc. (this company)$1.5B14.3%10.8%$195.7M
COSMCosmos Health Inc.$65.3M19.9%29.3%$20.8MMEDSDataMeds AI, Inc.$23.3M28.7%433.9%$4.1MSTEKStemtech Corp$2.9M43.1%140.7%$1.6MESYNEnerSyn Global Inc.$866.9K30.8%303.4%$46.4MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
NU Skin Enterprises, Inc. · CIK 1021561 · Engraved from SEC EDGAR